NATCO launches Anastrazole in the USA
June 29th 2011
NATCO Pharma Limited is pleased to announce the launch, in the United States of America, of the generic version of Anastrazole 1 mg. tablets, consequent to the final approval received from the US FDA.
The product has been launched through the company's marketing partners.
The company recorded an EPS of Rs. 17.31 on a consolidated basis for the year 2010, as against Rs. 15.62 last year.
Anastrazole is used in the treatment of breast cancers and the market for this product in the USA is expected to be in the region of US $ 750 Million per annum. The company is confident of gaining a reasonable share of the market.